Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ... - Nasdaq

Submitted by Anonymous (not verified) on Wed, 09/20/2017 - 12:38

Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ...NasdaqZug, Switzerland - September 20, 2017 - Shire plc (LSE: SHP, NASDAQ:SHPG) and its partner in Japan, Shionogi & Co., Ltd, announced that a Phase 3 study evaluating INTUNIV® (guanfacine hydrochloride prolonged release) in adult patients with attention ...